© 2022 MJH Life Sciences and Endocrinology Network. All rights reserved.
© 2022 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
April 21, 2022
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, evaluates upcoming CGM advances in the pipeline for the management of diabetes.
April 14, 2022
Dr Diana Isaacs reviews the significance of Eversense’s recent approval for a 180-day indication and the potential role of Dexcom G7 in the diabetes treatment landscape.
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, comments on the accuracy and selection of CGMs in treating diabetes and shares insight on the evolution of CGM systems over the past year.
April 07, 2022
An expert in diabetes management discusses the role of CGMs in treating diabetes during the COVID-19 pandemic and the benefits of using CGM in telemedicine.
Dr Diana Isaacs provides insight on patient factors to consider for CGM use in diabetes treatment.
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, reviews the advantages of CGMs in treating type 1 and type 2 diabetes and how CGMs can improve glycemic control and quality of life in patients.
February 23, 2022
An expert panel discusses where bempedoic acid currently fits into the treatment of hypercholesterolemia.
What pharmacists and providers need to know to counsel patients on when discussing the use of prescription or over-the-counter fish oil supplement as treatment for dyslipidemia and hypertriglyceridemia.
February 16, 2022
Takeaways of the REDUCE-IT trial of icosapent ethyl as treatment for dyslipidemia and hypertriglyceridemia.
An overview of the REDUCE-IT trial of icosapent ethyl for the management of triglycerides and prevention of cardiovascular events.